A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

This study tests AZD0486 — a new type of targeted therapy that brings immune T-cells close to cancer cells — in people with B-cell non-Hodgkin lymphoma (a type of blood cancer), either as a single treatment or combined with other agents. It includes groups for relapsed/refractory disease and newly diagnosed follicular lymphoma. **You may be eligible if...** - You have biopsy-proven B-cell non-Hodgkin lymphoma (including DLBCL, HGBL, or follicular lymphoma) - For relapsed/refractory disease: you have received at least 2 prior treatments and are not eligible for or have declined other options like CAR-T therapy - For newly diagnosed follicular lymphoma: your cancer is Stage II–IV and meets criteria requiring treatment - Your liver, kidneys, and bone marrow function are adequate - You have at least one measurable area of cancer **You may NOT be eligible if...** - Your cancer is CD19-negative (the target the drug uses) - Your overall health status is too poor (ECOG score greater than 2) - Your kidney function is significantly reduced Talk to your doctor to see if this trial is right for you.